Pacira Biosciences (PCRX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

PCRX · Stock Price

USD 23.64-1.48 (-5.89%)

Market Cap: $934.1M

Historical price data

Market Cap: $934.1MPipeline: 1 drugPatents: 20Founded: 2007HQ: Brisbane, United States

Sector Ranking#52 in Drug Delivery & Formulation

Overview

Pacira BioSciences is a mission-driven company dedicated to transforming pain management through innovative, non-opioid therapeutic solutions. Its commercial success is anchored by EXPAREL®, a sustained-release local analgesic, and the iovera° cryoneurolysis system, which together address critical needs in postsurgical and musculoskeletal pain. The company's strategy combines aggressive commercial execution, pipeline expansion into high-value chronic pain indications like osteoarthritis via gene therapy (PCRX-201), and robust advocacy to shape healthcare policy and expand access to non-opioid alternatives.

Pain ManagementMusculoskeletal Disorders

Technology Platform

Proprietary DepoFoam® multivesicular liposomal delivery system for sustained, controlled-release administration, complemented by cryoneurolysis (iovera°) and gene therapy platforms for targeted, non-opioid pain relief.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
Popliteal nerve block including liposomal bupivacaine + Addu...	Moderate-to-severely Painful Ankle Surgery	Approved

Funding History

2

Total raised:$64M

IPO$64MUndisclosedFeb 10, 2011

Series AUndisclosedUndisclosedJun 15, 2007

FDA Approved Drugs

2

ZILRETTANDAOct 6, 2017

EXPARELNDAOct 28, 2011

Opportunities

The recent passage of the NOPAIN Act creates a favorable reimbursement environment for non-opioid therapies in surgical settings, directly benefiting EXPAREL.

Furthermore, the vast, underserved market for chronic osteoarthritis pain presents a multi-billion dollar opportunity for pipeline assets like ZILRETTA, iovera°, and the novel gene therapy PCRX-201.

Risk Factors

Revenue remains heavily concentrated on EXPAREL, exposing the company to patent expiry, pricing pressure, and competitive threats.

The clinical and regulatory pathway for its most innovative asset, the gene therapy PCRX-201, is unproven and carries high technical and development risk.

Competitive Landscape

Pacira competes with generic opioids, other long-acting local anesthetics (e.g., Heron's HTX-011), intra-articular steroids, and device-based therapies like radiofrequency ablation. Its competitive moat is built on a first-mover commercial footprint, a multi-modal portfolio enabling combination use, and deep payer/provider relationships in pain management.